How Pfizer became the status vax

Cox is likely not the first Pfizerphile you’ve heard sing his vaccine brand’s praises. Pro-Pfizer sentiment is all over TikTok, where you can find skits of bros bonding over their shared Pfizer status, or one creator declaring that the name itself “Sounds rich. Decadent. Luxury!” Olajide Bamishigbin, a psychology professor in California, was on a similar wavelength recently when he tweeted a GIF of SpongeBob SquarePants dressed in a top hat and monocle alongside the words, “Me when somebody says they got any vaccine other than Pfizer.” The Pfizer superiority complex is at once a joke and a real phenomenon. But is it affecting the vaccine rollout? “Even though I think that we have this instinct that’s out there”—the belief that Pfizer is the elite shot—“it still feels more playful than really driving outcomes,” said Manuel Hermosilla, a professor of marketing at Johns Hopkins’ Carey Business School who studies the pharmaceutical industry. He said he thinks people understand that getting whatever vaccine you can should trump any brand preference—though it’s unclear how this week’s news about the Johnson & Johnson vaccine could change that equation. On Tuesday, U.S. health agencies recommended a pause in administration of the J&J vaccine, after six women developed a rare blood clot disorder within weeks of receiving the shot. In all likelihood, this pause will be temporary. (Hermosilla, like most of this article’s sources, spoke to Slate before the J&J pause took effect.)